


Remibrutinib

Cat. No.:	HY-128757		
CAS No.:	1787294-07-8		
Molecular Formula:	C ₂₇ H ₂₇ F ₂ N ₅ O ₃		
Molecular Weight:	507.53		
Target:	Btk		
Pathway:	Protein Tyrosine Kinase/RTK		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (246.29 mM; Need ultrasonic)

Concentration	Solvent	Mass	1 mg	5 mg	10 mg
			1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.9703 mL	9.8516 mL	19.7033 mL
	5 mM		0.3941 mL	1.9703 mL	3.9407 mL
	10 mM		0.1970 mL	0.9852 mL	1.9703 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (4.10 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (4.10 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (4.10 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Remibrutinib, is a potent and orally active bruton tyrosine kinase (BTK) inhibitor with an IC₅₀ value of 1 nM. Remibrutinib inhibits BTK activity with an IC₅₀ value of 0.023 μM in blood^[1]. Remibrutinib has the potential for Chronic urticaria (CU) treatment^[2].

IC₅₀ & Target

IC₅₀: 1 nM (BTK)^[1]

In Vitro

In a biochemical enzyme assay, Remibrutinib (example 6) inhibits Btk enzymatic activity with an IC₅₀ value of 1 nM^[1].

In vitro B cell activation assay, Remibrutinib inhibits Btk enzymatic activity in blood with an IC₅₀ value of 0.023 μM, the whole blood is collected from the abdominal aorta of anaesthetized adult male Lewis rats^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Blood Adv. 2022 Jul 7;bloodadvances.2022007952.
- ACS Pharmacol Transl Sci. 2023 Feb 10.
- Biomed Chromatogr. 2023 Aug 31;e5737.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Daniela Angst, et al. Novel amino pyrimidine derivatives. Patent WO2015079417A1.
- [2]. Kolkhir P, et al. New treatments for chronic urticaria. Ann Allergy Asthma Immunol. 2019 Aug 23.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA